There were a number of stocks that had managed to make a notable upward move on Tuesday and one of those was the Gb Sciences Inc (OTCMKTS:GBLX) stock, which clocked gains of as much as 11%. First of all, it is important for investors to take a look at the nature of the company before making their minds up about the stock.
Trading Data
On Tuesday, GBLX stock moved up 10.70% to $0.0300 with 162K shares, compared to its average volume of 170k shares. The stock moved within a range of $0.0271 – 0.0310 after opening trade at $0.0271.
About The Company
Gb Sciences is a pharmaceutical research and development firm that is focused on plant-inspired products. The company seeks to produce patented formulations from cannabis and other plans for targeting specific medical conditions. The therapeutic mixtures in question are meant for the prescription medicines market and are sold through GbS Global Biopharma Inc, which is a subsidiary of the company.
Gb Sciences is Leading Digital Transformation in Biopharma Industry Through Its Novel AI-Accelerated Drug Discovery Platform—PhAROS™
There has been some positive development in recent times as well. Not too long ago, Gb Sciences also managed to get pre-clinical data that supported its plant concept mixtures for the treatment of Cytokine Release Syndrome, a condition that is seen in COVID 19 infected patients.
Considering the fact that you now have a fair idea about the nature of Gb Sciences as a company, it may now be a good move for investors to take a look at the development from yesterday which may have led to the rally in the stock. One of the things that need to be understood is the fact that the life sciences industry is fast being digitized ever since the coronavirus pandemic emerged. However, Gb Sciences is one of the few pioneering companies which had been working on that front long before the onset of the coronavirus pandemic. A study that had been conducted by the consultancy giant Deloitte revealed that Biopharma had been one of the industries which was quite behind other industries with regard to digital transformation.
In this situation, it should be noted that Gb Sciences has come up with the Phytomedical Analytics for Research Optimization at Scale or the PhAROS platform that can help in the acceleration of medicine development. The platform deploys machine learning and data analytics in order to accelerate the entire process. It goes without saying that such a platform can often prove to be a major boon for the medicine development industry and make Gb Sciences one of the more influential companies in the industry.
Experts have noted that the platform developed by the company could well be the best possible tool with regard to the future of medicine development. The President and CSO of the company Dr. Andrea Small-Howard spoke about the company’s platform as well. She noted that the deployment of artificial intelligence and machine learning presents a major new untapped opportunity in the world of medicines.
It could help companies in discovering new options in plant-based medicines as well. At this point in time, the excitement around the Gb Sciences stock is perhaps completely understandable. It remains to be seen if the stock can continue to add to its gains over the coming days.
Key Quote
Gb Sciences’ President and CSO, Dr. Andrea Small-Howard, says, “The use of AI and computer modeling for biomedical research presents an untapped opportunity to discover plant-inspired medicines reflecting the vast knowledge of traditional medicines, but simplified. PhAROS™ uses machine learning to identify potentially effective combinations of drugs amongst the known traditional medicine systems in a complex view of human diseases. The PhAROS™ platform yields numerous potentially effective, plant-inspired combination drugs to help millions worldwide and also pre-screens these drug candidates for potentially unwanted side effects.”
Technical Data
GBLX stock is trading above the 20-Day and 50-Day Moving averages of $0.0239 and $0.0259 respectively. Moreover, the stock is trading above the 200-Day moving average of $0.0289. The company has a total market capitalization of $9.87 million. The stock is up 28% over the past month.
